Cross-sectional case-control studies (Blue)
The aim of this study was to describe the clinical characteristics and outcome of patients with cerebral venous sinus thrombosis after SARS-CoV-2 vaccination (Oxford-AstraZeneca and Janssen/Johnson&Johnson) with and without thrombocytopenia syndrome collected in an international registry, comparing them with a control group of patients with cerebral venous sinus thrombosis unrelated to SARS-CoV-2 vaccination. The authors found that patients with cerebral venous sinus thrombosis associated with thrombocytopenia following SARS-CoV-2 vaccination had a clearly distinct clinical profile compared to the control group, with higher rates of coma and intracerebral hemorrhage and a higher mortality rate. By contrast, patients with cerebral venous sinus thrombosis following SARS-CoV-2 vaccination who did not present associated thrombocytopenia, had similar clinical features and prognosis as patients of the control group.
Sánchez van Kammen M, Aguiar de Sousa D, Poli S, et al. Characteristics and Outcomes of Patients with Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. JAMA Neurol. 2021 Sep 28:e213619 doi: 10.1001/jamaneurol.2021.3619. Online ahead of print.